Karus Therapeutics is aiming to make the treatment of inflammatory diseases and cancer more effective through the development of best-in-class small-molecule drugs that target epigenetic mechanisms and lipid kinase signalling pathways.
The outstanding potency, efficacy and excellent tolerability of Karus’s HDAC inhibitors (HDI) represent a unique and innovative approach to this important drug target and brings the promise of a new gold-standard in the treatment of rheumatoid arthritis, psoriasis and cancer.
Karus’s lipid kinase signalling programme brings together a world-class research and development team that are using new insights to the design and development of innovative drugs to treat inflammatory disease and cancer.
|
As at 31 Dec 2012 |
IP Group holding |
IP Venture Fund* holding |
9.9% |
9.2% |
| |
*IP Group has a 10%
economic interest in IP
Venture Fund |
Holdings represent undiluted beneficial equity interest excluding debt